GlassScriptPhysician profile
Celeste Julayne Curnick
NPI 1184997348
$4,076.40
in general payments reported to CMS, 2019-2025
23 companies · $93.22 in 2025
The $93.22 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,377 · 2022: $1,264 · 2023: $32.01 · 2024: $1,311 · 2025: $93.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,227.51 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $607.41 | 2021-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $495.11 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $440.42 | 2021-2024 | Sucraid |
| Gilead Sciences, INC. | $240.90 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $197.85 | 2021-2022 | |
| Braintree Laboratories, INC. | $122.03 | 2021-2024 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $82.23 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $78.34 | 2021-2024 | |
| Genzyme Corporation | $75.11 | 2024 | |
| Redhill Biopharma INC. | $70.64 | 2021-2022 | |
| Pfizer INC. | $59.93 | 2024 | |
| Madrigal Pharmaceuticals | $59.16 | 2024 | Resmetirom |
| Merck Sharp & Dohme LLC | $59.14 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.67 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $47.18 | 2024 | Ibsrela |
| Boston Scientific Corporation | $34.16 | 2025 | Axonics |
| Phathom Pharmaceuticals, INC. | $32.21 | 2024 | Voquezna |
| Ethicon US, LLC | $21.43 | 2022 | |
| Celgene Corporation | $20.33 | 2022 | |
| Medtronic, INC. | $18.88 | 2024 | Interstim |
| Alnylam Pharmaceuticals INC. | $16.45 | 2022 | |
| Daiichi Sankyo INC. | $16.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Curnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.